The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Antiviral Research, Journal Year: 2020, Volume and Issue: 178, P. 104787 - 104787

Published: April 3, 2020

Although several clinical trials are now underway to test possible therapies, the worldwide response COVID-19 outbreak has been largely limited monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown have broad-spectrum anti-viral activity in vitro, is inhibitor of causative virus (SARS-CoV-2), with a single addition Vero-hSLAM cells 2 h post infection SARS-CoV-2 able effect ~5000-fold reduction viral RNA at 48 h. Ivermectin therefore warrants further investigation for benefits humans.

Language: Английский

---

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies

International Journal of Antimicrobial Agents, Journal Year: 2020, Volume and Issue: 56(2), P. 106054 - 106054

Published: June 10, 2020

Language: Английский

---

Host and viral determinants of influenza A virus species specificity

Nature Reviews Microbiology, Journal Year: 2018, Volume and Issue: 17(2), P. 67 - 81

Published: Nov. 28, 2018

Language: Английский

---

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

The Journal of Antibiotics, Journal Year: 2020, Volume and Issue: 73(9), P. 593 - 602

Published: June 12, 2020

Language: Английский

---

The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer

Antiviral Research, Journal Year: 2020, Volume and Issue: 177, P. 104760 - 104760

Published: March 3, 2020

Language: Английский

---

Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview

Viruses, Journal Year: 2018, Volume and Issue: 10(9), P. 497 - 497

Published: Sept. 13, 2018

Influenza A viruses (IAVs) possess a great zoonotic potential as they are able to infect different avian and mammalian animal hosts, from which can be transmitted humans. This is based on the ability of IAV gradually change their genome by mutation or even reassemble segments during co-infection host cell with strains, resulting in high genetic diversity. Variants circulating newly emerging IAVs continue trigger global health threats annually for both humans animals. Here, we provide an introduction IAVs, highlighting mechanisms viral evolution, spectrum, animal/human interface. Pathogenicity determinants mammals, special emphasis pandemic potential, discussed. Finally, overview provided various approaches prevention human infections.

Language: Английский

---

Host-Directed Antiviral Therapy

Clinical Microbiology Reviews, Journal Year: 2020, Volume and Issue: 33(3)

Published: May 12, 2020

Antiviral drugs have traditionally been developed by directly targeting essential viral components. However, this strategy often fails due to the rapid generation of drug-resistant viruses. Recent genome-wide approaches, such as those employing small interfering RNA (siRNA) or clustered regularly interspaced short palindromic repeats (CRISPR) using molecule chemical inhibitors cellular “kinome,” used successfully identify factors that can support virus replication.

Language: Английский

---

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Annals of Clinical Microbiology and Antimicrobials, Journal Year: 2020, Volume and Issue: 19(1)

Published: May 30, 2020

Language: Английский

---

Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance

New Microbes and New Infections, Journal Year: 2020, Volume and Issue: 35, P. 100684 - 100684

Published: April 22, 2020

Alarming situation has been caused due to the emergence of COVID-19 infection around world. There is an urgency developing a therapeutic strategy in order control spread COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have tested by diverse group researchers worldwide for their against novel coronavirus. The present report presents together comprehensive knowledge derived from major researches about above altogether context current health emergency Hydroxychloroquine were known act creating acidic environment inhibiting importin (IMPα/β1) mediated viral import. Azithromycin was found similar hydroxychloroquine as acidotropic lipophilic weak base. All three categories seemed potentially coronavirus infection. However, efficacies need be studied detail individually combination in-vivo combat

Language: Английский

---

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

American Journal of Therapeutics, Journal Year: 2021, Volume and Issue: 28(3), P. e299 - e318

Published: April 22, 2021

After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel repurposed therapeutic agents were used empirically studied within trials.

Language: Английский

---